Standout Papers

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in A... 2004 2026 2011 2018 623
  1. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer (2004)
    Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 40 from Science/Nature 146 standout
Sub-graph 1 of 18

Citing Papers

The biology and management of non-small cell lung cancer
2018 StandoutNature
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
2016 StandoutScience
39 intermediate papers

Works of Natalie Memoli being referenced

Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
2004 Standout
O-188 Encouraging activity and durable responses demonstrated by the epithelial growth factor receptor-tyrosine kinase inhibitor, Erlotinib (Tarceva TM, OSI774), in patients with advanced bronchioloalveolar (BAC) cell carcinoma
2003
and 2 more

Author Peers

Author Last Decade Papers Cites
Natalie Memoli 682 613 258 7 862
Hui-Ping Liu 556 473 217 12 753
F. Gamza 999 962 213 5 1.2k
George Blumenschein 428 663 389 8 889
Jonathan Noble 559 494 247 6 832
Renee Iacona 563 516 235 12 799
J‐M Verdebout 407 424 313 11 777
Jonathan S. Goldberg 591 522 352 9 937
Tzu-Hsiu Chen 594 578 419 7 854
Bianco Ar 428 607 325 7 831
Damiano 433 604 327 5 837

All Works

Loading papers...

Rankless by CCL
2026